title: Negotiating the maze of biotech "tool patents".
abstract: Circumventing existing patents may be a shortcut to getting your recombinant protein to market.
authors.affiliation: Celtrix Pharmaceuticals, Santa Clara, CA 95054-1815, USA. desmond@celtrix.com
authors.forename: D
authors.initials: D
authors.lastname: Mascarenhas
mesh_terms: D001709:Biotechnology; D017008:Negotiating; D010330:Patents as Topic; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins